Cargando…

Alemtuzumab: COVID-19 infection and severe depletion of T-lymphocyte: case report

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7378975/ http://dx.doi.org/10.1007/s40278-020-81008-5

Ejemplares similares

Alemtuzumab: COVID-19 infection: case report
Publicado: (2020)

Mild COVID-19 infection in a patient with multiple sclerosis and severe depletion of T-lymphocyte subsets due to alemtuzumab
por: Guevara, Carlos, et al.
Publicado: (2020)

Alemtuzumab/cladribine/natalizumab: Lymphopenia and COVID-19 infection: case report
Publicado: (2021)

Alemtuzumab: Infections: 4 case reports
Publicado: (2020)

Alemtuzumab/natalizumab/ocrelizumab: COVID-19: 3 case reports
Publicado: (2021)

Alemtuzumab: Haemophagocytic lymphohistiocytosis: case report
Publicado: (2021)

A case of Alemtuzumab-induced neutropenia in multiple sclerosis in association with the expansion of large granular lymphocytes
por: Vakrakou, A. G., et al.
Publicado: (2018)

Alemtuzumab in chronic lymphocytic leukemia
por: Fraser, G., et al.
Publicado: (2007)

Alemtuzumab-associated diffuse alveolar damage – a case report
por: Bayas, Antonios, et al.
Publicado: (2020)

Alemtuzumab/methylprednisolone: Coronavirus disease-2019: 2 case reports
Publicado: (2020)

Norovirus-related chronic diarrhea in a patient treated with alemtuzumab for chronic lymphocytic leukemia
por: Ronchetti, Anne-Marie, et al.
Publicado: (2014)

Alemtuzumab as initial therapy for Sézary syndrome: A report of 2 cases
por: Brumfiel, Caitlin M., et al.
Publicado: (2020)

Alemtuzumab in refractory Sézary syndrome
por: Reifs, Carmen María Alcántara, et al.
Publicado: (2016)

Listeria monocytogenes infection associated with alemtuzumab – - a case for better preventive strategies
por: Holmøy, Trygve, et al.
Publicado: (2017)

Potential COVID-19 infection in patients with severe multiple sclerosis treated with alemtuzumab
por: Matías-Guiu, Jorge, et al.
Publicado: (2020)

Listeria Meningitis Complicating Alemtuzumab Treatment in Multiple Sclerosis—Report of Two Cases
por: Rau, Daniela, et al.
Publicado: (2015)

Alemtuzumab/varicella-zoster-virus-vaccine-live: Chicken pox, asymptomatic COVID and lack of efficacy: case report
Publicado: (2021)

Immune reconstitution 20 years after treatment with alemtuzumab in a rheumatoid arthritis cohort: implications for lymphocyte depleting therapies
por: Cooles, Faye A. H., et al.
Publicado: (2016)

A case of autoimmune myositis after treatment with alemtuzumab for multiple sclerosis
por: Aouad, Patrick, et al.
Publicado: (2018)

Renal-Limited Antiglomerular Basement Membrane Disease Related To Alemtuzumab: A Case Report
por: Harrigan, Amye M., et al.
Publicado: (2020)

Lymphocyte pharmacodynamics are not associated with autoimmunity or efficacy after alemtuzumab
por: Wiendl, Heinz, et al.
Publicado: (2019)

Alemtuzumab in Covid era
por: Iovino, Aniello, et al.
Publicado: (2021)

Diffuse alveolar hemorrhage during alemtuzumab infusion in a patient with multiple sclerosis: a case report
por: Myro, Aija Zuleron, et al.
Publicado: (2018)

Alemtuzumab‐induced petechiae and epistaxis in a patient with relapsing–remitting multiple sclerosis: A case report
por: Mahmoudi, Farhad, et al.
Publicado: (2023)

Both cladribine and alemtuzumab may effect MS via B-cell depletion
por: Baker, David, et al.
Publicado: (2017)

Alemtuzumab
por: Tridente, Giuseppe
Publicado: (2013)

First-line treatment of chronic lymphocytic leukemia: role of alemtuzumab
por: Schweighofer, Carmen Diana, et al.
Publicado: (2010)

Vitamin D supplementation for the prevention or depletion of side effects of therapy with alemtuzumab in multiple sclerosis
por: Goischke, Hans-Klaus
Publicado: (2019)

CD52-targeted depletion by Alemtuzumab ameliorates allergic airway hyperreactivity and lung inflammation
por: Shafiei-Jahani, Pedram, et al.
Publicado: (2021)

Highly active RRMS and ocrelizumab after failure of alemtuzumab therapy
por: Vališ, Martin, et al.
Publicado: (2020)

Ibrutinib for chronic lymphocytic leukemia in the setting of respiratory failure from severe COVID‐19 infection: Case report and literature review
por: Lin, Adam Yuh, et al.
Publicado: (2020)

Severe case of covid-19 infection in children: Case report
por: Maarad, M., et al.
Publicado: (2021)

COVID-19 and multiple sclerosis: A description of two cases on alemtuzumab
por: Fernández-Díaz, Eva, et al.
Publicado: (2020)

Rescue therapy with alemtuzumab in B cell/antibody-mediated multiple sclerosis
por: Akgün, Katja, et al.
Publicado: (2018)

Failure of alemtuzumab therapy in three patients with MOG antibody associated disease
por: Seneviratne, Sinali O., et al.
Publicado: (2022)

Two case reports of acquired haemophilia A as complications of alemtuzumab treatment for multiple sclerosis
por: Gounder, Kuhilan, et al.
Publicado: (2021)

Antineoplastics: COVID-19 infection and emergence of ibrutinib resistance in chronic lymphocytic leukaemia: case report
Publicado: (2021)

Alemtuzumab Plus Cyclosporine Treatment of the Autoimmune Hemolytic Anemia in an Adult Bowel Transplant
por: Lauro, A., et al.
Publicado: (2014)

Abdominal Lymphocyte-Depleted Hodgkin Lymphoma: A Rare Presentation
por: Kasinathan, Ganesh, et al.
Publicado: (2019)

Adalimumab/methotrexate/prednisone: Severe COVID-19 infection: case report
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fn6gr3ql1e3qgiuqouc6q83s02